YAP1 and epithelioid hemangioendothelioma: This will be straightforward for cancers driven by mutations known to cause YAP or TAZ activation, such as NF2-mutant mesothelioma [22], GNAQ-mutant uveal melanoma [23], Epithelioid Hemangioendothelioma (EHE) (which is driven by the oncogenic TAZ-CAMTA1 fusion protein [24,25,26]), and other cancers driven by YAP fusions [27].